EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSAMXG00000002883
Gene Symbol: ATP1A1
1 Cross references
297 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSAMXG00000014095
Gene Symbol: ATP1A2A
1 Cross references
206 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSAMXG00000031054
Gene Symbol: ATP1B3A
1 Cross references
229 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSAMXG00000037984
Gene Symbol: ATR
1 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSAMXG00000009805
Gene Symbol: AXL
2 Cross references
188 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSAMXG00000011513
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

B1 Bradykinin Receptor-Like

Ensembl ID : ENSAMXG00000026333
Gene Symbol: LOC103041516
3 Cross references
149 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSAMXG00000001829
Gene Symbol: BCL2
2 Cross references
142 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSAMXG00000031499
Gene Symbol: BCL2L1
1 Cross references
229 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSAMXG00000016321
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSAMXG00000006667
Gene Symbol: LOC103044160
3 Cross references
213 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSAMXG00000002336
Gene Symbol: BTK
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).